Individualizing Pazopanib therapy by exploRing the role of Early metabolic responsE and drug exposure as a preDICTor for treatment outcome in patients with STS - PREDICT

Medische Oncologie0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1) Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.
•2) Age >= 18 years or legal age of consent if greater than 18 years.
•3) Histological confirmed diagnosis of selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
•4) Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
•5) Measurable disease criteria (RECIST 1.1).
•6) No radio-, chemo- or tumor specific targeted therapy within the last 4 weeks prior to study entry.
•7) Adequate organ system function.
•8) Minimal evaluable laesion of >= 15mm.

•1) Prior malignancy.
•2) Central nervous system (CNS) metastases at baseline
•3) Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding
•4) Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product
•5) Corrected QT interval (QTc) > 480msecs

发起方

Medische Oncologie